TUKYSA Drug Patent Profile

Which patents cover Tukysa, and what generic alternatives are available?

Tukysa is a drug marketed by Seagen and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and eighty-seven patent family members in forty-four countries.

The generic ingredient in TUKYSA is tucatinib. One supplier is listed for this compound. Additional details are available on the tucatinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Tukysa

Tukysa was eligible for patent challenges on April 17, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 19, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TUKYSA

International Patents:	187
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	17
Patent Applications:	1,131
Drug Prices:	Drug price information for TUKYSA
What excipients (inactive ingredients) are in TUKYSA?	TUKYSA excipients list
DailyMed Link:	TUKYSA at DailyMed

See drug prices for TUKYSA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TUKYSA

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH RAS WILD-TYPE, HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY

NDA:

213411

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TUKYSA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
RemeGen Co., Ltd.	Phase 1/Phase 2
Jonathan Riess	Phase 1
National Cancer Institute (NCI)	Phase 1

See all TUKYSA clinical trials

Pharmacology for TUKYSA

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors Tyrosine Kinase Inhibitors

US Patents and Regulatory Information for TUKYSA

TUKYSA is protected by seven US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH RAS WILD-TYPE, HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No			Y	Y
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No			Y

EU/EMA Drug Approvals for TUKYSA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Seagen B.V.	Tukysa	tucatinib	EMEA/H/C/005263Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑HER2 treatment regimens.	Authorised	no	no	no	2021-02-11

International Patents for TUKYSA

When does loss-of-exclusivity occur for TUKYSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TUKYSA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018258663	Treatment of HER2 positive cancers
Australia	2022241509	Treatment of HER2 positive cancers
Brazil	112019022280	tratamento de cânceres de her2 positivo
Canada	3060407	TRAITEMENT DES CANCERS POSITIFS A HER2 (TREATMENT OF HER2 POSITIVE CANCERS)

Supplementary Protection Certificates for TUKYSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1971601	C01971601/01	Switzerland		PRODUCT NAME: TUCATINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67798 07.05.2020
1971601	301113	Netherlands		PRODUCT NAME: TUCATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: 67798 20200507
1971601	CA 2021 00025	Denmark		PRODUCT NAME: TUCATINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; NAT. REG. NO/DATE: EU/1/20/1526 20210212; FIRST REG. NO/DATE: CH 67798 20200507
1971601	LUC00217	Luxembourg		PRODUCT NAME: TUCATINIB EVENTUELLEMENT SOUS FORME D'UN SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/20/1526 20210212

Tukysa Market Dynamics, Financial Trajectory, Patent Exclusivity, and Generic Risk

Last updated: August 4, 2026

Tukysa, the branded name for tucatinib, became a strategic oncology asset for Seagen and Pfizer through its use in HER2-positive breast cancer and HER2-positive colorectal cancer. Product sales increased from about $70 million in 2020 to approximately $354 million in 2023. Growth has been driven by the HER2CLIMB regimen, central nervous system activity, and expansion into colorectal cancer. The principal commercial risk is competition from Enhertu, Kadcyla, Perjeta, and other HER2-directed therapies rather than immediate generic substitution.

How large is the Tukysa market?

Tukysa addresses HER2-positive cancers, a commercially important segment of oncology with established antibody, antibody-drug conjugate, and tyrosine kinase inhibitor competition.

The breast cancer indication is for Tukysa in combination with trastuzumab and capecitabine for patients with unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, after at least one prior anti-HER2-based regimen in the metastatic setting. The FDA approved this indication on April 17, 2020.[1]

The colorectal indication was approved on January 19, 2023, for adult patients with unresectable or metastatic HER2-positive colorectal cancer who have received prior chemotherapy based on fluoropyrimidine, oxaliplatin, and irinotecan, and prior anti-VEGF and anti-EGFR therapy when appropriate.[2]

What clinical attributes support Tukysa demand?

Tukysa has several commercial advantages:

• It is an oral, selective HER2 tyrosine kinase inhibitor.
• It has activity in patients with brain metastases, an important unmet need in HER2-positive breast cancer.
• The HER2CLIMB regimen demonstrated an overall survival benefit in previously treated metastatic breast cancer.
• It is used with trastuzumab and capecitabine rather than as a stand-alone treatment.
• It offers a treatment option after disease progression on multiple HER2-directed therapies.

Its limitations include diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, and the burden of administering a three-drug regimen. Enhertu and Kadcyla are delivered intravenously but can offer stronger positioning in earlier lines of treatment.

How have Tukysa sales changed over time?

Seagen reported rapid sales growth after launch. The product benefited from its initial breast cancer approval and the expanded colorectal indication.

Fiscal year	Tukysa net product sales	Approximate year-over-year change	Primary commercial driver
2020	$70 million	New launch	Initial metastatic breast cancer uptake
2021	$212 million	203%	HER2CLIMB adoption and broader physician use
2022	$304 million	43%	Continued breast cancer expansion
2023	$354 million	16%	Mature breast cancer demand and colorectal launch

Sources: Seagen annual reports and Form 10-K filings.[3-6]

The trajectory shows a transition from launch-stage growth to a more mature branded oncology product. The 2023 growth rate was lower than in the first two full commercial years, which indicates a larger revenue base and increasing competitive pressure. The colorectal indication added market reach but has a narrower eligible population and later-line positioning than the breast cancer indication.

What is Tukysa’s revenue exposure for Pfizer?

Pfizer acquired Seagen in March 2024 in a transaction valued at approximately $43 billion.[7] Tukysa became part of Pfizer’s Global Oncology portfolio, alongside established products and pipeline programs in breast, prostate, hematologic, and other cancers.

Tukysa is strategically relevant because it provides:

1. A commercial product with recurring oncology revenue.
2. An oral HER2 therapy with central nervous system positioning.
3. Combination potential with other HER2-directed medicines.
4. A platform for additional tumor-specific or sequencing strategies.

The principal financial exposure is concentrated in HER2-positive breast cancer. The colorectal indication is commercially useful but is unlikely by itself to offset major erosion in breast cancer if newer antibody-drug conjugates displace Tukysa in treatment sequencing.

How does Tukysa compare with competing HER2 drugs?

Tukysa competes within a treatment landscape that includes antibody-drug conjugates, monoclonal antibodies, and oral kinase inhibitors.

Product	Active ingredient	Company	Modality	Main competitive position
Tukysa	Tucatinib	Pfizer	Oral HER2 TKI	Later-line breast cancer, brain metastases, colorectal cancer
Enhertu	Trastuzumab deruxtecan	Daiichi Sankyo/AstraZeneca	Antibody-drug conjugate	Broad HER2-positive and HER2-low breast cancer use
Kadcyla	Ado-trastuzumab emtansine	Roche	Antibody-drug conjugate	Adjuvant and metastatic HER2-positive breast cancer
Perjeta	Pertuzumab	Roche	Monoclonal antibody	Earlier-line combination treatment
Nerlynx	Neratinib	Puma Biotechnology	Pan-HER TKI	Extended adjuvant breast cancer and later-line use
Tykerb	Lapatinib	GSK	HER2/EGFR TKI	Older later-line breast cancer regimen
Margenza	Margetuximab	MacroGenics	Monoclonal antibody	Later-line HER2-positive breast cancer

Enhertu is the most important competitive threat. Its efficacy and expanding use across HER2 expression levels can move patients earlier in the treatment pathway, reducing the population reaching Tukysa. Tukysa retains a distinct position in patients with brain metastases and in combination regimens supported by HER2CLIMB data.

What is the FDA regulatory status of Tukysa?

The FDA approved Tukysa under the traditional approval pathway for metastatic HER2-positive breast cancer in 2020.[1] The colorectal indication was approved in 2023 based on the MOUNTAINEER study.[2]

Regulatory milestone	Date
FDA approval for HER2-positive metastatic breast cancer	April 17, 2020
FDA approval for HER2-positive metastatic colorectal cancer	January 19, 2023
Seagen acquired by Pfizer	March 2024

The label requires monitoring of liver function and management of diarrhea. Tucatinib is metabolized primarily through CYP2C8 and CYP3A pathways, creating drug-interaction considerations. Its adverse-event profile and oral administration affect prescribing decisions, particularly when compared with intravenous antibody-drug conjugates.

What patents protect Tukysa?

Tukysa’s U.S. intellectual-property position includes composition, pharmaceutical formulation, and method-of-use protection. The core compound is associated with U.S. Patent No. 10,272,083, assigned to Seagen-related entities and originating from the tucatinib development program.[8]

The relevant patent categories are:

Composition-of-matter patents

Composition patents protect tucatinib and related chemical compounds. These patents generally provide the strongest protection because a competing product cannot lawfully market the same active ingredient before expiration unless it successfully challenges the patent or obtains a license.

Formulation patents

Formulation protection can cover pharmaceutical compositions, dosage forms, excipients, and stability characteristics. Formulation patents are less comprehensive than composition patents because a generic applicant may attempt to design around them while preserving the same active ingredient.

Method-of-use patents

Method patents can cover use of tucatinib in HER2-positive breast cancer, colorectal cancer, brain metastases, treatment combinations, or particular patient populations. Their value depends on whether the patented use is commercially important and whether the prescribing and reimbursement environment makes induced infringement litigation practical.

The FDA Orange Book is the controlling public source for listed patents and their use codes. The commercial patent horizon extends into the early 2030s based on the listed core-patent estate, subject to patent-term adjustment, patent-term extension, pediatric exclusivity, and the scope of any later-issued patents.[9]

When does Tukysa lose exclusivity?

Tukysa’s five-year new chemical entity exclusivity began on the April 17, 2020 approval date and generally prevented the filing of an abbreviated new drug application until April 2024.[1,10]

That regulatory exclusivity does not itself determine the earliest commercial generic entry date. Patent challenges, litigation, settlement agreements, court rulings, and any 180-day first-filer exclusivity can materially change the timing.

Exclusivity element	Indicative timing or status
Five-year new chemical entity exclusivity	April 17, 2020 to April 17, 2025
Earliest standard ANDA filing window	April 17, 2024
Core patent horizon	Early 2030s, based on listed patent protection
Generic launch before patent expiry	Possible only through challenge, settlement, license, or successful design-around
Biosimilar pathway	Not applicable because tucatinib is a small molecule

The colorectal approval may provide separate regulatory protection only to the extent that FDA grants a qualifying period of new clinical investigation exclusivity for the relevant supplemental application. Such protection is indication-specific and does not necessarily block generic entry for all approved uses.

Are generic companies challenging Tukysa?

As of June 2024, no publicly reported Paragraph IV litigation or major ANDA challenge had established a generic entry date for tucatinib. The absence of a public challenge does not eliminate future risk. Once the NCE filing bar expired in April 2024, ANDA activity became more plausible.

A generic applicant would likely evaluate:

• The validity and enforceability of the composition patent.
• Whether listed method-of-use patents can be carved out.
• The commercial value of the breast cancer and colorectal indications.
• The ability to design around formulation claims.
• The risk of a launch before patent expiry.
• The potential for a settlement with Pfizer.

The strongest barrier is likely the composition-of-matter estate. Method-of-use patents may influence the timing and scope of a launch but generally provide narrower protection.

What patent litigation and settlement risks affect Tukysa?

No significant publicly reported Tukysa patent settlement had been announced through June 2024. A future Paragraph IV dispute could involve:

1. Invalidity challenges based on obviousness, anticipation, written description, or enablement.
2. Non-infringement arguments directed to specific formulation or use claims.
3. Carve-out labeling for unpatented indications.
4. A negotiated entry date before the latest patent expiry.
5. Authorized-generic or licensing provisions.

For Pfizer, the commercial value of settlement depends on the size of Tukysa revenue at the time of challenge. For a generic company, the expected value depends on whether the market supports a launch before the early-2030s patent horizon.

How strong is the Tukysa patent estate?

Tukysa has a commercially meaningful patent estate, but its strength is uneven across claim types.

Protection type	Relative strength	Commercial implication
Tucatinib composition	High	Main barrier to substitutable generic entry
Tablet and formulation claims	Medium	May support litigation but can be vulnerable to design-around strategies
Breast cancer methods	Medium to high	Important where the labeled regimen is widely prescribed
Colorectal cancer methods	Medium	Narrower population and later approval reduce stand-alone value
CNS or biomarker-specific methods	Variable	Value depends on claim scope and clinical adoption

The estate is stronger than a product protected only by method patents, but it is not immune to invalidity attacks. Revenue concentration in one therapeutic class also creates competitive risk that patent protection cannot solve.

What licensing deals shaped Tukysa development?

Tucatinib was developed through the Cascadian Therapeutics program. Seattle Genetics acquired Cascadian in 2018 for approximately $614 million, gaining control of tucatinib and related development assets.[11]

Seagen later became the commercial sponsor and secured the FDA approvals. Pfizer’s 2024 acquisition of Seagen transferred the Tukysa commercial and intellectual-property position to Pfizer.

The transaction history indicates that tucatinib was acquired before approval, with much of its value realized through clinical development, regulatory approval, and commercial launch rather than through a post-approval licensing arrangement.

What generic launch scenarios exist for Tukysa?

Three scenarios are commercially relevant.

Scenario 1: Patent-protected launch after the early 2030s

This is the base case if Pfizer maintains the core patent estate and no successful Paragraph IV challenge accelerates entry.

Scenario 2: Earlier entry through Paragraph IV litigation

A first-filing generic could challenge composition or formulation patents. A successful invalidity or non-infringement ruling could produce entry years before the nominal patent expiry.

Scenario 3: Negotiated settlement

Pfizer could permit entry on an agreed date in exchange for a release of patent claims. Settlement terms could include a licensed generic, restrictions on launch timing, or limitations tied to particular indications.

The economic impact of generic entry would likely be rapid because oral oncology products can face substantial price erosion once multiple ANDA-approved competitors enter.

Key Takeaways

• Tukysa sales rose from approximately $70 million in 2020 to $354 million in 2023.
• Pfizer acquired Tukysa through its $43 billion acquisition of Seagen in March 2024.
• The product’s core commercial differentiation is activity in HER2-positive disease involving the brain.
• Enhertu is the most significant competitive threat because of its expanding efficacy and earlier-line use.
• Tucatinib’s five-year NCE exclusivity began in April 2020, with the ANDA filing bar ending in April 2024.
• The core patent estate extends into the early 2030s based on publicly listed protection.
• No major public Paragraph IV litigation or settlement had established a generic launch date through June 2024.
• Tukysa is a small molecule, so biosimilar competition is not relevant.
• Future erosion risk depends more on Enhertu displacement and treatment sequencing than on immediate generic entry.

FAQs About Tukysa Market and Patent Risk

What is Tukysa used for?

Tukysa is used with trastuzumab and capecitabine for certain patients with unresectable or metastatic HER2-positive breast cancer and HER2-positive metastatic colorectal cancer.

Is Tukysa a biologic or a small molecule?

Tukysa contains tucatinib, an orally administered small-molecule tyrosine kinase inhibitor. Generic, rather than biosimilar, competition is the relevant substitution risk.

Does Tukysa work against brain metastases?

Yes. Tucatinib has clinical evidence in patients with HER2-positive breast cancer and brain metastases, which is a central part of its market positioning.

Who owns Tukysa?

Pfizer owns Tukysa following its acquisition of Seagen in March 2024. Seagen previously acquired Cascadian Therapeutics, the company developing tucatinib, in 2018.

When could a generic version of Tukysa launch?

A generic could potentially launch before the early-2030s patent horizon if a Paragraph IV challenge succeeds or Pfizer reaches a settlement permitting earlier entry. Without an accelerated entry agreement or court victory, patent protection remains the main barrier.

References

1. U.S. Food and Drug Administration. (2020, April 17). FDA approves tucatinib with trastuzumab and capecitabine for unresectable advanced or metastatic HER2-positive breast cancer. https://www.fda.gov

2. U.S. Food and Drug Administration. (2023, January 19). FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer. https://www.fda.gov

3. Seagen Inc. (2021). 2020 annual report and Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov

4. Seagen Inc. (2022). 2021 annual report and Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov

5. Seagen Inc. (2023). 2022 annual report and Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov

6. Seagen Inc. (2024). 2023 annual report and Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov

7. Pfizer Inc. (2023). Pfizer completes acquisition of Seagen. https://www.pfizer.com

8. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 10,272,083. https://patents.google.com

9. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

10. U.S. Food and Drug Administration. (n.d.). Approved drug product exclusivity information. https://www.fda.gov

11. Seattle Genetics, Inc. (2018). Seattle Genetics to acquire Cascadian Therapeutics. https://www.sec.gov

DrugChatter Q&A for TUKYSA

Tukysa patent expiryukysa eu?
Tukysa patent publication?
Tukysa wholesale acquisition cost per month?
Tukysa tablets price in india?
Tukysa mechanism of action?